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Abstract
The adoptive transfer of immune cells for cancer, chronic infection, and autoimmunity is an 
emerging field that has shown promise in recent trials. The transgenic adenocarcinoma mouse 
prostate (TRAMP) is a classical mouse model of prostate cancer (PCa) and TRAMP cell lines 
were derived from a TRAMP mouse tumor. TRAMP-C2 is tumorigenic when subcutaneously 
(s.c.) grafted into syngeneic C57BL/6 host mice (Foster et al., 1997). This protocol will describe 
the adoptive transfer of purified CD11b+Gr1+ double positive (DP) myeloid-derived suppressor 
cells (MDSC) and CD3+ T cells in the TRAMP-C2 prostate cancer mouse model in order to 
establish the intrinsic functionality of these immune cells and to determine their role in 
tumorigenesis in vivo (Yan et al., 2014).
 Materials and Reagents
1. RPMI 1640 (Life Technologies, Gibco®, catalog number: 22400-089)
2. Trypan blue 0.4% solution (Lonza, catalog number: 17-942E)
3. Myeloid-Derived Suppressor Cell Isolation Kit (mouse) (Miltenyi Biotec, 
catalog number: 130-094-538)
4. Pan T Cell Isolation Kit II, mouse (Miltenyi Biotec, catalog number: 
130-095-130)
5. Antibodies for flow cytometry: Ly-6G-FITC (Gr1, RB6-8C5), CD11b-PE 
(M1/70), and CD3-FITC (17A2) (Biolegend, catalog numbers: 108405, 
01207, and 100203 respectively)
6. MACS® BSA Stock Solution (Miltenyi Biotec, catalog number: 
130-091-376)
7. AutoMACS® Rinsing Solution (Miltenyi Biotec, catalog number: 
130-091-222)
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8. Phosphate buffer saline (PBS) (see Recipes)
9. Sterile red blood cell lysis buffer (RBC lysis buffer) (see Recipes)
10. MACS buffer (see Recipes)
 Equipment
1. LS column (Miltenyi Biotec, catalog number: 130-042-401)
2. MidiMACS Separator (Miltenyi Biotec, catalog number: 130-042-302)
3. MACS MultiStand (Miltenyi Biotec, catalog number: 130-042-303)
4. Wide field microscope (Nikon Diaphot Phase Contrast Inverted 
Laboratory Microscope, catalog number: 805426)
5. Sterile forceps and scissors
6. Flow cytometer
7. 1 ml syringes (29 G) (BD Biosciences, catalog number: 329410)
8. Sterile Cell strainers 70 µm (BD Biosciences, catalog number: 352350)
9. 15 ml conical tubes (BD Biosciences, catalog number: 352095)
10. Tabletop centrifuge
11. Cell culture centrifuge
12. Sterile culture hood
13. Hemocytometer
14. 60 mm cell culture dish
 Procedure
A. Isolation of splenocytes
1. Prepare a single cell suspension from mouse (TRAMP-C2 
tumor bearing, about 4 months old) spleens in the sterile 
culture hood. Disrupt the spleen with the plunger of a 1 ml 
syringe against a 70-µm cell strainer in a 60 mm petri dish 
filled with 2 ml of RPMI1640.
2. Centrifuge single cell suspensions in 15 ml conical tubes at 
300 × g for 10 min at RT.
3. Re-suspend the splenocytes with 5 ml of RBC lysis buffer 
and incubate 5 min at RT. Dilute with 10 ml PBS and 
centrifuge for 10 min at 300 × g. Re-suspend cell pellet in 
5 ml MACS buffer (4 °C) and count viable cell numbers 
using a 0.4% Trypan blue solution. Each spleen yields 
about 200 × 106 splenocytes.
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4. One spleen can provide enough Gr1+CD11b+ DP cells for 
transplantation of 3 experimental mice; the CD3+ cells 
isolated from one spleen is also enough for transplantation 
of 3 experimental mice. Splenocytes from 2–3 individual 
spleens can be pooled before immune cell purification.
B. CD11b+Gr1+ DP cells purification from splenocytes using Miltenyi 
Myeloid-Derived Suppressor Cell Isolation Kit (mouse, a kit for positive 
isolation of cells)
1. Centrifuge cell suspension at 300 × g for 10 min at 4 °C in 
the 15 ml conical tubes. Aspirate supernatant completely.
2. Re-suspend cell pellet in 350 µl of MACS buffer per 108 
total cells.
3. Add 50 µl of FcR Blocking Reagent per 108 total cells.
4. Mix well and incubate for 10 min in the refrigerator (2–
8 °C).
5. Add 100 µl of Anti-Ly-6G-Biotin (MDSC-Kit).
6. Mix well and incubate for 10 min in the refrigerator (2–
8 °C).
7. Wash cells by adding 10 ml of MACS buffer per 108 cells 
and centrifuge at 300 × g for 10 min at 4 °C. Aspirate 
supernatant completely.
8. Re-suspend up to 108 cells in 800 µl of MACS buffer.
9. Add 200 µl of Anti-Biotin MicroBeads.
10. Mix well and incubate for 15 min in the refrigerator (2–
8 °C).
11. Wash cells by adding 10 ml of MACS buffer per 108 cells 
and centrifuge at 300 × g for 10 min at 4 °C. Aspirate 
supernatant completely.
12. Re-suspend up to 108 cells in 500 µl of MACS buffer.
13. Place the LS column in the magnetic field of a MidiMACS 
separator.
14. Equilibrate the column by rinsing with 3 ml of MACS 
buffer.
15. Apply the cell suspension onto the column; collect flow-
through containing unlabeled cells.
16. Wash the column with 3 × 3 ml of MACS buffer and 
collect unlabeled cells that pass through and combine with 
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the effluent from step B15; keep unlabeled cells on ice 
until further processing.
17. Remove the column from the separator and place it in a 15 
ml conical tube.
18. Pipette 5 ml of MACS buffer onto the column; 
immediately flush out the magnetically labeled cells by 
firmly pushing the plunger into the column and collect 
CD11b+Gr1+ DP cells.
19. Count viable cell numbers using a 0.4% Trypan blue 
solution. Set aside 2 × 105 cells for evaluating purification 
efficiency as described below.
C. Miltenyi T cells purification from splenocytes using Pan T Cell Isolation 
Kit II (mouse, a kit for negative isolation of cells)
1. Count and centrifuge unlabeled cell suspension from steps 
B15–16; re-suspend cell pellet in 400 µl MACS buffer per 
108 total cells.
2. Add 100 µl of Biotin-Antibody Cocktail per 108 total cells.
3. Mix well and incubate for 5 min in the refrigerator (2–
8 °C).
4. Add 300 µl of MACS buffer per 108 total cells.
5. Add 20 µl of Anti-Biotin MicroBeads per 108 total cells.
6. Mix well and incubate for 10 min in the refrigerator (2–
8 °C).
7. Place a LS Column in the magnetic field of a MidiMACS 
Separator.
8. Prepare the column by rinsing with 3 ml of MACS buffer.
9. Apply cell suspension onto the column and collect flow-
through containing unlabeled cells, representing the 
enriched T cells.
10. Wash the column with 3 ml of MACS buffer and collect 
unlabeled cells that pass through, representing the enriched 
T cells; combine with the effluent from step C9.
11. Count viable cell numbers using 0.4% Trypan Blue 
solution. Set aside 2 × 105 cells for evaluating purification 
efficiency as described below.
D. Control of purification efficiency by flow cytometry
1. Stain 2 × 105 total cells (step B19) with 20 µl of a 
suspension contained pre-titrated amounts of anti-mouse 
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Ly-6G and anti-mouse CD11b. The antibodies are 1:100 
diluted in PBS with 1% BSA.
2. Stain 2 × 105 total cells (step C11) with 20 µl of a 
suspension contained pre-titrated amounts of anti-mouse 
CD3.
3. Incubate 30 min at 4 °C and wash in 150 µl of washing 
buffer (PBS with 1% BSA).
4. Centrifuge cell suspension at 4 °C and 500 × g for 5 min. 
Discard supernatant and keep the cell pellet.
5. Re-suspend in 200 µl of washing buffer (PBS with 1% 
BSA) and analyze in a flow cytometer.
E. Mouse prostate cancer model and tail vein injection (≥ 5 mice/group)
1. Mice with C57/Bl6 background are subcutaneously (s.c.) 
injected with TRAMP-C2 cells (3 × 106 cells in 0.2 ml 
PBS per mouse) on the same day of the adoptive transfer 
of immune cells (Yan et al., 2014). On day 7 and day 14 
post-injections, an additional two doses of purified 
CD11b+Gr1+ DP cells (5 × 106 cells per mouse) or 
purified CD3+ T cells (5 × 106 cells per mouse) need to be 
adoptively transferred via intravenous injection. Mice will 
be sacrificed when they appeared moribund (45 days).
2. Warm up the mice under a lamp for 5 min to achieve 
vasodilation for tail vein injection. Inject purified 
CD11b+Gr1+ DP cells (5 × 106 cells/200 µl PBS per 
mouse) or purified CD3+ T cells (5 × 106 cells/200 µl PBS 
per mouse) in the lateral tail vein with a 1 ml-syringe with 
a 29 G needle.
3. Tumor development will be closely monitored, and tumor 
size will be measured every 7 days.
 Recipes
1. RBC lysis buffer
0.15 M NH4Cl
1 mM NaHCO3
0.1 mM EDTA dissolved in sterile double distilled water
Adjust pH to 7.2–7.4 with 1 M HCl
Filter sterilize
2. Phosphate buffer saline (PBS)
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136 mM NaCl
8.2 mM Na2HPO4
1.5 mM KH2PO4
2.7 mM KCl (pH 7.4)
3. MACS buffer
Prepare a solution containing phosphate-buffered saline (PBS) 
(pH 7.2), 0.5% bovine serum albumin (BSA), and 2 mM EDTA 
by diluting MACS® BSA Stock Solution1:20 with 
autoMACS® Rinsing Solution.
Keep buffer cold (2–8 °C).
Degas buffer before use, as air bubbles may block the column.
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Figure 1. 
The purity of CD11b+Gr1+ DP cells (Gr1 and CD11b antibodies) and CD3+ T cells (CD4 
and CD3 antibodies) can be assessed by FACS analyses
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Figure 2. 
DP, but not T cells from tumor challenged WT mice were sufficient to permit tumor growth 
in ogr1−/− mice injected with TRAMP0C2 cells. (Yan et al., 2014)
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